Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

Too, 1/2012 is a long way from now. I am more worried about holding a buck through 2018.

Assuming the share float is 20 million by then, without FDA approval but granted accelerated status $4 or an $80 million market cap?

With FDA approval the PPs maybe 10x that number($40, market cap 800 million)?

In the event of a partnership and FDA approval the PPS could be 15x ($60, market cap 1.2 billion)?

I continue to hold my nose and dollar cost average purchases as only buyers post split will make any real money here.

The BOD and PN are certainly increasing their shares (at our expense). 20k of options puts most of the BOD in the top 10 on the institutional list of ownership. PN with 130,000 new shares now has roughly as many shares as the top four institutions and dwarfs UT.

Like I said would happen before the reverse split, the deck is stacked in PN's favor.

As long as PN has enough funds to run the company why move the trials forward? He makes 600k per year and 130,000 in options. The longer it takes to move the drug forward, the more shares he will have IF the Prexigebersen is ever finally approved. I do not see any need for urgency on management's part and the contrary may be true.

Here is an update on the institutional ownership:

https://www.nasdaq.com/symbol/bpth/institutional-holdings